Back
Created on:
August 16, 2023
PXMD Business Update
Business Briefing: SIGNIFICANT PHASE 3 PAX-HAT-301 STUDY RESULTS; PROGRESSING TOWARD START OF MULTI-CENTEREDCLINICAL TRIALS IN ASD
Business Briefing: SIGNIFICANT PHASE 3 PAX-HAT-301 STUDY RESULTS; PROGRESSING TOWARD START OF MULTI-CENTEREDCLINICAL TRIALS IN ASD
